Clinical Trials Logo

Adverse Reactions clinical trials

View clinical trials related to Adverse Reactions.

Filter by:
  • None
  • Page 1

NCT ID: NCT04473703 Not yet recruiting - Cardiac Event Clinical Trials

Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor in NSCLC Patients

Start date: August 1, 2020
Phase:
Study type: Observational

This is a prospective, open label, single arm study. A total of 300 patients with primary non-small cell lung cancer treated with PD-1/PD-L1 immune checkpoint inhibitors(ICIs) are expected to included . All patients will follow up for at least 1 year. Patients with cardiac adverse reactions after PD-1/PD-L1 immune checkpoint inhibitor treatment at admission or during the subsequently follow-up period will randomly assigned a random number to each patient by computer random sequence. Patients with odd random number will treat with RASI(renin-angiotensin system inhibitors), and those with even random number will treat with ARNI(angiotensin-receptor-neprilysin inhibitor).